Skip to main content
SWOG logo

User account menu

  • Log in

Main navigation

  • About
    • History & Impact
    • Mission & Values
    • Leadership
    • Support SWOG
    • Join SWOG
    • Policies & Procedures
    • Careers
    • Contact Us
  • The SWOG Network
    • How We Work
    • Our Staff
    • Our Advocates
    • Our Partners
  • News & Events
    • News
    • SWOG Meetings
    • For Press
  • Clinical Trials
    • Biospecimen Submission
    • Biospecimen Access
    • Data Requests
    • Clinical Trials Search
    • Clinical Research Resources
    • Frequently Asked Questions
    • Publications
    • Institutions
    • Quality Assurance & Audits
    • Serious Adverse Events
    • Training Resources
    • ORP (CRA) Workbench
    • Protocol Workbench
  • Workbenches
    • ORP (CRA) Workbench
    • Protocol Workbench
    • VA Workbench
  • For Patients
    • Patient & Advocate Voices
    • Trials Open to Patients
    • About SWOG Cancer Trials
    • Joining a Trial
    • Results of SWOG Trials

Section navigation

  • Recent Updates
    • 11/1/2026
    • 10/15/2026
    • 10/1/2026
    • 9/15/2026
    • 9/1/2026
    • 8/15/2026
    • 8/1/2026
    • 7/15/2026
    • 7/1/2026
    • 6/15/2026
    • 6/1/2026
    • 5/15/2026
    • All Updates

Breadcrumb

  1. SWOG
  2. Member Resources
  3. Trial & Business Updates
  4. Other

Priority List Other

S1802
III
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
S2507
II
A Phase II Randomized Study of Blinatumomab with or without Revumenib for Patients with KMT2A Translocation B-Cell Acute Lymphoblastic Leukemia (ALL)/ Acute Leukemia With Ambiguous Lineage (ALAL) with Persistent Measurable Residual Disease (MRD)
S9808
Other
Long Term Follow-Up Protocol: An Administrative Tool.
SWOG logo

Footer: Social Links

  • LinkedIn
  • Twitter
  • YouTube
Copyright © 2026

Footer

  • Disclaimer